Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
36.9M
-
Shares change
-
+603K
-
Total reported value, excl. options
-
$133M
-
Value change
-
+$3.19M
-
Number of buys
-
20
-
Number of sells
-
-18
-
Price
-
$3.60
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2017
53 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2017.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.9M shares
of 193M outstanding shares and own 19.07% of the company stock.
Largest 10 shareholders include QVT Financial LP (16M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (5.29M shares), RTW INVESTMENTS, LP (5.21M shares), PRIMECAP MANAGEMENT CO/CA/ (3.95M shares), D. E. Shaw & Co., Inc. (1.73M shares), BANK OF MONTREAL /CAN/ (874K shares), AXA (781K shares), K2 PRINCIPAL FUND, L.P. (376K shares), MORGAN STANLEY (327K shares), and Hudson Bay Capital Management LP (295K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.